Live
- 2024 on track to be hottest year on record
- PM Modi’s visit to Solapur: Women applaud ‘Double-Engine’ government’s initiatives
- Nagarkurnool MLA Dr. Kuchukulla Rajesh Reddy Campaigning in Maharashtra Elections
- Wife Kills Husband with Her Lover: Details of Veldanda Murder Case Revealed by SP Gaikwad
- Strict Action on Violations of Food Rights: Telangana Food Commission Chairman Goli Srinivas Reddy
- Smooth Conduct of Group-3 Exams with Strict Security Measures: Collector Badavath Santosh
- Delhi HC orders cancellation of LOC issued against Ashneer Grover, wife
- Shami’s absence a major blow for India in BGT, says Paul Adams
- Will organize protests at borders if attack on minority Hindus in Bangladesh not stopped: Bengal LoP
- Dutch Ambassador Marisa Gerard Meets Telangana CM A. Revanth Reddy in Delhi
Dr Reddy’s gets zero observations for Miyapur center
Shares of Dr Reddy’s Lab closed higher Rs172.85 or 7.47 percent at Rs2,486.45 on BSE. The market valuation of Dr Reddy\'s Lab went up by Rs2,864.35 crore to Rs 41,223.35 crore.
Hyderabad: Global drug major Dr Reddy’s Laboratories Ltd (DRL) on Thursday said that it has received zero observations for its custom pharmaceutical services (CPS) facility, technology development centre (TDC-1) at Miyapur in Hyderabad. US FDA has completed audit of CPS and TDC-1 facilities with zero observations, according to a communique to BSE.
Shares of Dr Reddy’s Lab closed higher Rs172.85 or 7.47 percent at Rs2,486.45 on BSE. The market valuation of Dr Reddy's Lab went up by Rs2,864.35 crore to Rs 41,223.35 crore.
- Receives EIR for its Srikakulam plant; stock soars over 7%; mcap rises by `2,864 cr
On NSE, shares of the company soared 7.42 per cent to close at Rs2,486.55.In a separate filing to BSE, the drug major said that it has also received establishment inspection report (EIR) from the US health regulator for a unit of its Srikakulam plant in Andhra Pradesh.
The company has received EIR from the United States Food and Drug Administration (US FDA) for its formulations manufacturing facility at Srikakulam unit II. However, the company did not state if the US health regulator had made any observation in the EIR.
